Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 7/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775809 | 0.86 | PARP1 (0.36) | IDO1PARP1GABRA5MAPK14MAPK13 | |
| SCHEMBL5771839 | 0.84 | SIRT2 (0.40) | CA2SIRT2IDO1GABRA5 | |
| SCHEMBL5772554 | 0.82 | FFAR4 (0.46) | IDO1PARP1 | |
| SCHEMBL5776636 | 0.82 | SIRT2 (0.37) | CA2SIRT2GABRA5MAPK14MAPK13 | |
| SCHEMBL5771214 | 0.78 | FFAR4 (0.39) | IDO1GABRA5 | |
| SCHEMBL5777368 | 0.77 | SIRT2 (0.40) | SIRT2IDO1GABRA5PTGS2 | |
| SCHEMBL5777075 | 0.74 | CA2 (0.38) | CA2SIRT2IDO1CYP1A2CYP2D6 | |
| SCHEMBL5775299 | 0.70 | ADORA2A (0.38) | GABRA5PTGS2 | |
| SCHEMBL3223595 | 0.68 | AHR (0.38) | IDO1GABRA5PTGS2 | |
| SCHEMBL5769963 | 0.68 | MEN1 (0.41) | IDO1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | CA2 981/4885SIRT2 1426/4885IDO1 1275/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | CA2 988/4885SIRT2 738/4885IDO1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.